For the study, researchers looked at 269 men of whom 156 had prostate cancer. The researchers looked at the number of copies of the UGT2B7 gene and found that although deletion patterns for UGT2B17 and UGT2B28 genes were between 3.4 percent and 19.9, this did not increase the risk for prostate cancer.
"We did not see any association between polymorphism of UGT2B17 and UGT2B28 with cancer," Setlur said during Tuesday's teleconference.
For more about cancer, visit the American Cancer Society.
SOURCES: April 21, 2009, teleconference with: John S. Witte, Ph.D., professor, Institute for Human Genetics, University of California, San Francisco; Charles Mullighan, M.D., Ph.D., assistant member, St. Jude Children's Research Hospital, Memphis, Tenn.; Xifeng Wu, M.D., Ph.D., professor, Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston; Susan Slager, Ph.D., associate professor of biostatistics, Mayo Clinic, Rochester, Minn.; Sunita Setlur, Ph.D., instructor in pathology, Brigham and Women's Hospital and Harvard Medical School, Boston; Gangning Liang, M.D., Ph.D., associate professor of research, Department of Urology, University of Southern California, Los Angeles; presentations, American Association for Cancer Research 100th Annual Meeting, Denver